Search Videos by Topic or Participant
Browse by Series:

Investigational Therapies for Thyroid Cancer

Insights From: Robert I. Haddad, MD, Dana-Farber; Matthew H. Taylor, MD, Oregon Health;R. Michael Tuttle, MD, MSKCC
Published: Saturday, May 23, 2015
For High-Definition, Click
Beyond sorafenib and lenvatinib, other agents have also shown a clinical activity in the thyroid cancer setting, states Robert I. Haddad, MD. Some of these agents are currently available, while others are still in the testing phases.

Haddad shares the following options:
  • Pazopanib: a tyrosine kinase inhibitor, approved for renal cell carcinoma and other indications and currently in a phase II trial for advanced thyroid disease
  • Vandetanib: a multikinase inhibitor, approved for medullary thyroid carcinoma (MTC) and currently in phase II studies for patients with more aggressive types of thyroid cancer
  • Vemurafenib: a BRAF inhibitor, approved for metastatic melanoma. Has shown activity in phase II trials for patients with thyroid cancer
  • Everolimus: an mTOR inhibitor, with several ongoing trials, including combination studies
  • Cabozantinib: a multikinase inhibitor, currently approved for MTC, and being tested for RAI-resistant thyroid cancer
Along with vemurafenib, Haddad adds, the entire class of BRAF inhibitors is being tested in patients with BRAF mutations. Another area of ongoing investigation is immunotherapy, which may be tested as a stand-alone approach or in combination with some of the VEGF inhibitors.

Since the best approach in patients who have progressed on sorafenib and lenvatinib is unknown, Haddad notes that the next step in care would be enrollment in a clinical trial, but stresses the importance of profiling to determine which trial would be best.
Slider Left
Slider Right
For High-Definition, Click
Beyond sorafenib and lenvatinib, other agents have also shown a clinical activity in the thyroid cancer setting, states Robert I. Haddad, MD. Some of these agents are currently available, while others are still in the testing phases.

Haddad shares the following options:
  • Pazopanib: a tyrosine kinase inhibitor, approved for renal cell carcinoma and other indications and currently in a phase II trial for advanced thyroid disease
  • Vandetanib: a multikinase inhibitor, approved for medullary thyroid carcinoma (MTC) and currently in phase II studies for patients with more aggressive types of thyroid cancer
  • Vemurafenib: a BRAF inhibitor, approved for metastatic melanoma. Has shown activity in phase II trials for patients with thyroid cancer
  • Everolimus: an mTOR inhibitor, with several ongoing trials, including combination studies
  • Cabozantinib: a multikinase inhibitor, currently approved for MTC, and being tested for RAI-resistant thyroid cancer
Along with vemurafenib, Haddad adds, the entire class of BRAF inhibitors is being tested in patients with BRAF mutations. Another area of ongoing investigation is immunotherapy, which may be tested as a stand-alone approach or in combination with some of the VEGF inhibitors.

Since the best approach in patients who have progressed on sorafenib and lenvatinib is unknown, Haddad notes that the next step in care would be enrollment in a clinical trial, but stresses the importance of profiling to determine which trial would be best.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing Chemotherapy Induced Nausea and VomitingOct 31, 20182.0
Publication Bottom Border
Border Publication
x